Altai Capital Management L.P. Buys New Shares in OraSure Technologies, Inc. $OSUR

Key Points

• Altai Capital Management L.P. acquired 157,915 shares of OraSure Technologies, Inc. valued at approximately $532,000, making it the firm's 5th largest holding.
• 93.50% of OraSure Technologies' stock is currently owned by institutional investors, indicating significant institutional interest in the company.
• Analysts have given OraSure Technologies a consensus rating of "Hold" with a price target of $3.00, reflecting cautious sentiment towards the stock's performance.

Altai Capital Management L.P. acquired a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 157,915 shares of the medical instruments supplier's stock, valued at approximately $532,000. OraSure Technologies comprises 0.9% of Altai Capital Management L.P.'s investment portfolio, making the stock its 5th biggest holding. Altai Capital Management L.P. owned approximately 0.21% of OraSure Technologies at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of OSUR. Tower Research Capital LLC TRC lifted its holdings in OraSure Technologies by 202.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 5,234 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in OraSure Technologies in the fourth quarter worth approximately $37,000. Gotham Asset Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter valued at $43,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of OraSure Technologies in the first quarter valued at $49,000. Finally, Quantbot Technologies LP acquired a new stake in OraSure Technologies during the 1st quarter valued at $52,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, May 17th. Evercore ISI reaffirmed an "in-line" rating and issued a $3.00 price target on shares of OraSure Technologies in a research note on Monday, May 19th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $3.00.

OraSure Technologies Price Performance

NASDAQ:OSUR traded down $0.06 during trading hours on Monday, reaching $3.18. The company's stock had a trading volume of 69,187 shares, compared to its average volume of 752,771. The company has a market cap of $232.22 million, a price-to-earnings ratio of -4.75 and a beta of 0.44. OraSure Technologies, Inc. has a one year low of $2.36 and a one year high of $4.60. The business's 50-day moving average is $3.09 and its 200-day moving average is $3.07.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.